Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793182 | 0.82 | ADORA1 (0.40) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL1908991 | 0.81 | USP2 (0.36) | SMN1; SMN2USP2NR1H2HPGDALDH1A1 | |
| SCHEMBL426525 | 0.79 | SMN1; SMN2 (0.41) | ADORA1SMN1; SMN2USP2NR1H2HPGD | |
| SCHEMBL1909264 | 0.79 | ALOX15 (0.34) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL13957491 | 0.78 | ADORA1 (0.39) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL22233140 | 0.77 | ADORA1 (0.39) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL606911 | 0.77 | SMN1; SMN2 (0.44) | ADORA1SMN1; SMN2USP2GAAHPGD | |
| SCHEMBL428115 | 0.77 | ADORA1 (0.39) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL25245654 | 0.77 | SMN1; SMN2 (0.42) | ADORA1SMN1; SMN2USP2NR1H2GAA | |
| SCHEMBL23390397 | 0.77 | USP2 (0.39) | ADORA1SMN1; SMN2USP2NR1H2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | ADORA1 3248/4885SMN1; SMN2 3099/4885USP2 1176/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | ADORA1 3248/4885SMN1; SMN2 3099/4885USP2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.